One of the most important features of prostate cancer (PC) is the diverse biological activity attributed to heterogeneity within individual cancers. We hypothesize that metabolic difference identified by proton MR-spectroscopy (MRS) might be related to diverse biological potential resulting from heterogeneous cancer cell populations and well reflect the biological aggressiveness of PC.
INTRODUCTION AND OBJECTIVES:
One of the most important features of prostate cancer (PC) is the diverse biological activity attributed to heterogeneity within individual cancers. We hypothesize that metabolic difference identified by proton MR-spectroscopy (MRS) might be related to diverse biological potential resulting from heterogeneous cancer cell populations and well reflect the biological aggressiveness of PC.
METHODS: In this study, 113 cases that underwent RALP were included. All patients performed 1.5T MRS examination prior to RALP. On MRS, each peak of the chemical shift between 0.5 and 4.2 ppm was determined by the computer-assisted objective measurement of MRS, and evaluated by cluster analysis or principal component analysis for measuring heterogeneity within individual cancers. The 1st principal component was considered as an index related to heterogeneity within individual cancers. The mean value, standard deviation (SD), coefficient of variation (CV) of the target shifts such as choline (3.2 ppm), citrate (2.6 ppm), N-acetyl-L-aspartate (NAA) (2.0 ppm) and alanine (1.48 ppm) were also calculated and compared with pathological findings as well as biochemical recurrence (BCR).
RESULTS: Representative heatmaps of 2 different PC cases were shown in Figure. In this study, a correlation between the mean value and SD was positive in choline and NAA, (p<0.0001, both), while it was weak in alanine (p¼0.0479). Based on this, the SD was used as an index of variation for choline and NAA, while the CV was used for alanine. The measured mean heterogeneity of our series predicted by the 1st principal component was 21.4%, which showed a significant correlation with SD for choline and NAA (p¼0.0011and p<0.0001, respectively). On the other hand, the 1st principal component did not correlate with the CV for alanine, PSA or Gleason score. Although 8 out of 113 patients progressed into BCR, multivariate analysis showed that the SD for choline, followed by PSA and the SD for NAA, was an independent predictor of BCR (p¼0.0354, p¼0.0624 and p¼0.0952, respectively).
CONCLUSIONS: To our knowledge, this is the first report of comprehensive analysis of MRS pattern to validate intra-tumor heterogeneity in PC, which can surely develop diagnostic and therapeutic strategy of PC. (ccRCC) is the most common histology among these SRMs. Current AS algorithms largely rely on growth parameters of the masses measured over time. We sought to identify genomic biomarkers that could potentially refine the management of SRMs, especially in patients being evaluated for AS.
Source of
METHODS: From four databases, we identified 205 patients who had SRMs (<4 cm) at time of surgery and had sequencing performed on their primary tumors. We included patients from our institutional prospective database (n¼25), and from three publicly available cohorts, The Cancer Genome Atlas (n¼110), University of Tokyo (n¼38), and The International Cancer Genome Consortium (n¼32). We analyzed the frequency of recurrent somatic mutations among the entire cohort. Using Chi-Square analysis, the frequency of mutations that occurred in at least 5% of patients were compared in patients who had recurrence or died from their disease during follow-up with those who did not. Kaplan-Meier survival plots were generated for these frequently mutated genes. Analysis was adjusted for multiple testing using the false discovery rate.
RESULTS: Median follow-up was 43.1 months among survivors. Mutations in VHL, PBRM1, SETD2, BAP1, KDM5C, and MTOR were present in more than 5% of tumors. Of the 205 patients, 25 (12.2%) had recurrence or died of their disease. Mutations in KDM5C e492 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 
